Managing the Tafasitamab Triplet: Safety Profile, Adverse Events, and Clinical Implications from inMIND

In this episode, 'Managing the Tafasitamab Triplet: Safety Profile, Adverse Events, and Clinical Implications from inMIND,' Christina Poh, MD explores the following questions:

What does the inMIND safety data tell us about the tolerability of tafasitamab in combination with lenalidomide and rituximab? How does it compare to the lenalidomide and rituximab backbone alone?

What were the most clinically significant adverse events observed in the tafasitamab arm, and how manageable were they in the trial context?

Christina Poh reviewed the inMIND safety data, noting that the addition of tafasitamab to the lenalidomide and rituximab backbone produced a manageable safety profile that was generally consistent with the R² backbone alone with no major unexpected safety signals observed and overall good patient tolerability throughout the trial. She identified hematologic toxicity, specifically neutropenia, as the most clinically significant adverse event in the tafasitamab arm, and also noted higher rates of COVID-19 pneumonia in the tafasitamab combination arm compared to the standard of care arm, all of which were treated and resolved with standard supportive care approaches without requiring significant protocol modifications.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

The next episode in this series, 'Why Clinicians May Consider Obinutuzumab Over Rituximab in Follicular Lymphoma,' features Christina Poh advancing her conversation on follicular lymphoma and focusing on how she weighs the tolerability burden of obinutuzumab against its efficacy, and the specific patient profiles where she would favor one anti-CD20 agent over the other.